Mymetics (Mymetics) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is Mymetics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Mymetics is: No Data: Cannot be evaluated.

Competitive Comparison of Mymetics's Risk Assessment

For the Biotechnology subindustry, Mymetics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mymetics's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Mymetics's Risk Assessment falls into.

Mymetics (OTCPK:MYMX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Mymetics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Mymetics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Mymetics (Mymetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066

Website

https://www.mymetics.com

Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.

Executives

Marcel B. Ruegg	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard	officer: President, CEO, CFO	ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering	director, officer: President and CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard	director	C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin	officer: CEO	40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann	officer: CSO	KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern	director	815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin	director	POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury	officer: CSO	CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd.	10 percent owner	C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd	10 percent owner	ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet	director, officer: CEO	14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer	director, officer: vp corp development
Ernst Lubke	director, officer: CFO	39, ROUTE D'ARZIER, ARZIER V8 CH-1273